LifeStance Health Group (LFST) to Post Earnings on Thursday

LifeStance Health Group (NASDAQ:LFST) is anticipated to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect LifeStance Health Group to announce earnings of $0.0328 per share and revenue of $414.5840 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. The company had revenue of $403.48 million during the quarter, compared to the consensus estimate of $387.46 million. LifeStance Health Group had a return on equity of 1.56% and a net margin of 1.55%.LifeStance Health Group’s revenue for the quarter was up 21.2% compared to the same quarter last year. On average, analysts expect LifeStance Health Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

LifeStance Health Group Trading Down 2.7%

Shares of NASDAQ LFST opened at $10.26 on Wednesday. The business has a 50 day simple moving average of $9.77 and a 200 day simple moving average of $7.99. LifeStance Health Group has a 52 week low of $3.81 and a 52 week high of $11.76. The stock has a market cap of $3.98 billion, a price-to-earnings ratio of 171.00 and a beta of 1.14. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.48 and a current ratio of 1.48.

Insiders Place Their Bets

In other LifeStance Health Group news, Director Darren M. Black sold 5,899,661 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total transaction of $47,315,281.22. Following the transaction, the director owned 23,310,115 shares in the company, valued at $186,947,122.30. This trade represents a 20.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Eric Shuey sold 243,362 shares of LifeStance Health Group stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total transaction of $1,951,763.24. Following the completion of the transaction, the director directly owned 867,562 shares in the company, valued at approximately $6,957,847.24. This represents a 21.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 7,687,394 shares of company stock valued at $63,579,701 over the last 90 days. 3.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of LFST. Bayesian Capital Management LP bought a new stake in LifeStance Health Group during the second quarter valued at about $52,000. Cibc World Markets Corp bought a new position in shares of LifeStance Health Group in the fourth quarter worth about $77,000. CIBC Bancorp USA Inc. bought a new position in shares of LifeStance Health Group in the third quarter worth about $78,000. Jump Financial LLC bought a new position in shares of LifeStance Health Group in the second quarter worth about $79,000. Finally, Qtron Investments LLC acquired a new position in shares of LifeStance Health Group during the 4th quarter worth about $83,000. Institutional investors own 85.50% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Wall Street Zen cut shares of LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. Barclays raised their price target on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a report on Tuesday, July 14th. Canaccord Genuity Group lifted their price objective on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Weiss Ratings reiterated a “hold (c-)” rating on shares of LifeStance Health Group in a report on Wednesday, May 27th. Finally, BTIG Research increased their target price on shares of LifeStance Health Group from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $11.50.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.